Literature DB >> 4032023

Nimodipine levels in gerbil brain following parenteral drug administration.

D S Heffez, T S Nowak, J V Passonneau.   

Abstract

Nimodipine binding to the particulate fraction of gerbil brain homogenate was characterized using tritiated (3H)-nimodipine as the radioactive ligand. Binding was monophasic and saturable, with the apparent affinity constant (KD) = 0.4 nM and the maximum number of binding sites (Bmax) = 12 nmol/kg wet wt. A competitive binding assay was validated for the measurement of nimodipine using gerbil brain as the source of receptors for the drug. Binding characteristics were sufficiently similar in specimens from different animals to allow the use of homogenates from individual animals as the source of both membrane-binding sites and competing ligand. Nimodipine could be detected in the brains of animals sacrificed soon after drug injection, and reached a peak level within 15 minutes. Brain drug level at a given time was a linear function of dose administered. One hour after a 1-mg/kg dose, the level of drug measured in brain was approximately 100 nmol/kg wet wt, more that 200 times the KD. Sufficient drug to mediate a maximal pharmacological effect accumulated in brain even after a dose of only 0.25 mg/kg. Thus, in this species, effective tissue nimodipine levels may be achieved at doses which minimize the risk of systemic hypotension.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4032023     DOI: 10.3171/jns.1985.63.4.0589

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  9 in total

1.  Effect of calcium antagonists on regional cerebral blood flow in transplanted rat brain tumors.

Authors:  K Matsukado; K Ikezaki; T Nomura; M Fukui
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

2.  In vivo specific binding characteristics and pharmacokinetics of a 1,4-dihydropyridine calcium channel antagonist in the senescent mouse brain.

Authors:  S Uchida; S Yamada; Y Deguchi; M Yamamoto; R Kimura
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

3.  Maturation of rat cerebellar Purkinje cells reveals an atypical Ca2+ channel current that is inhibited by omega-agatoxin IVA and the dihydropyridine (-)-(S)-Bay K8644.

Authors:  Elizabeth W Tringham; C Elizabeth Payne; Jonathan R B Dupere; Maria M Usowicz
Journal:  J Physiol       Date:  2006-11-23       Impact factor: 5.182

4.  Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.

Authors:  Lucy Colbourne; Paul J Harrison
Journal:  Mol Psychiatry       Date:  2022-05-26       Impact factor: 15.992

Review 5.  Drugs acting on calcium channels: potential treatment for ischaemic stroke.

Authors:  B J Alps
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

6.  Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study.

Authors:  R W Seiler; P Grolimund; H R Zurbruegg
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

7.  'Therapeutic window's for multiple drug treatment of experimental cerebral ischemia in gerbils.

Authors:  D B Stanimirovic; D V Micic; M Markovic; M Spatz; B B Mrsulja
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

8.  Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine against ischaemic injury in the hippocampus of the Mongolian gerbil.

Authors:  B J Alps; C Calder; W K Hass; A D Wilson
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

9.  Penetration of adenosine antagonists into mouse brain as determined by ex vivo binding.

Authors:  J Baumgold; O Nikodijevic; K A Jacobson
Journal:  Biochem Pharmacol       Date:  1992-02-18       Impact factor: 5.858

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.